litlas
ログインアカウント作成

David G. Maloney

1980–2025 年に発表

200
論文数
47,498
被引用数
110
h 指数
193
i10 指数

被引用数

David G. Maloney の年別被引用数1948 年: 被引用 1 件1980 年: 被引用 2 件1981 年: 被引用 3 件1982 年: 被引用 7 件1983 年: 被引用 18 件1984 年: 被引用 19 件1985 年: 被引用 15 件1986 年: 被引用 10 件1987 年: 被引用 9 件1988 年: 被引用 5 件1989 年: 被引用 9 件1990 年: 被引用 4 件1991 年: 被引用 4 件1992 年: 被引用 4 件1993 年: 被引用 3 件1994 年: 被引用 6 件1996 年: 被引用 6 件1997 年: 被引用 11 件1998 年: 被引用 21 件1999 年: 被引用 46 件2000 年: 被引用 69 件2001 年: 被引用 91 件2002 年: 被引用 129 件2003 年: 被引用 232 件2004 年: 被引用 222 件2005 年: 被引用 332 件2006 年: 被引用 218 件2007 年: 被引用 261 件2008 年: 被引用 282 件2009 年: 被引用 246 件2010 年: 被引用 278 件2011 年: 被引用 215 件2012 年: 被引用 204 件2013 年: 被引用 202 件2014 年: 被引用 176 件2015 年: 被引用 197 件2016 年: 被引用 202 件2017 年: 被引用 304 件2018 年: 被引用 433 件2019 年: 被引用 1,327 件2020 年: 被引用 1,828 件2021 年: 被引用 1,934 件2022 年: 被引用 1,734 件2023 年: 被引用 1,324 件2024 年: 被引用 2,107 件2025 年: 被引用 984 件2026 年: 被引用 25 件1949〜1979 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,969 件、この内訳の 32.4%中国: 引用元論文 1,164 件、この内訳の 7.6%ドイツ: 引用元論文 1,131 件、この内訳の 7.4%イギリス: 引用元論文 870 件、この内訳の 5.7%フランス: 引用元論文 804 件、この内訳の 5.2%イタリア: 引用元論文 752 件、この内訳の 4.9%スペイン: 引用元論文 570 件、この内訳の 3.7%オランダ: 引用元論文 470 件、この内訳の 3%カナダ: 引用元論文 440 件、この内訳の 2.9%スイス: 引用元論文 394 件、この内訳の 2.6%オーストラリア: 引用元論文 368 件、この内訳の 2.4%日本: 引用元論文 348 件、この内訳の 2.3%
0%32.4%その他 19.9%

機関

分野

  • Medicine89.9%
  • Immunology and Microbiology5.1%
  • Biochemistry, Genetics and Molecular Biology3.7%
  • Engineering0.4%
  • Neuroscience0.2%
  • Materials Science0.2%
  • その他0.5%

トピック

  • CAR-T cell therapy research17.7%
  • Hematopoietic Stem Cell Transplantation5.8%
  • Lymphoma Diagnosis and Treatment5.7%
  • Immune Cell Function and Interaction5.2%
  • Virus-based gene therapy research4.3%
  • Nanowire Synthesis and Applications3.1%
  • その他58.2%

共著者

全論文

検索で開く
  1. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

    著者: Jeremy S Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostić, Mary Mallaney, K. OGASAWARA, Kathryn J. Newhall, Yeonhee Kim, D. Li, Tanya Siddiqi - The Lancet 2020 被引用: 2,331

  2. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

    著者: Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger, Theodore A. Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine M. Melville, Barbara Pender, Tanya M Budiarto, Emily Robinson, Natalia N Steevens, Colette Chaney, Lorinda Soma, Xueyan Chen, Cecilia C.S. Yeung, Brent L. Wood, Daniel Li, Jianhong Cao, Shelly Heimfeld, Michael C. Jensen, Stanley R. Riddell, David G. Maloney - Journal of Clinical Investigation 2016 被引用: 2,103

  3. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

    著者: Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, K. OGASAWARA, Timothy R. Mack, Jeremy S Abramson - The Lancet 2022 被引用: 752

  4. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

    著者: Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal, Basem M. William, Javier Muñoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub‐Agha, Olalekan O. Oluwole, Henry C. Fung, Joseph D. Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu - The Lancet Oncology 2021 被引用: 617

  5. Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

    著者: Juliane Gust, Kevin A. Hay, Laïla‐Aïcha Hanafi, Daniel Li, David Myerson, Luis F. Gonzalez‐Cuyar, Cecilia C.S. Yeung, W. Conrad Liles, Mark Wurfel, José A. López, Junmei Chen, Dominic W. Chung, Susanna Harju-Baker, Tahsin Özpolat, Kathleen R. Fink, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle - Cancer Discovery 2017 被引用: 1,364

  6. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

    著者: Kevin A. Hay, Laïla‐Aïcha Hanafi, Daniel Li, Juliane Gust, W. Conrad Liles, Mark M. Wurfel, José A. López, Junmei Chen, Dominic W. Chung, Susanna Harju-Baker, Sindhu Cherian, Xueyan Chen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle - Blood 2017 被引用: 1,112

  7. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

    著者: Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frédéric Baron, Brenda M. Sandmaier, David G. Maloney, Barry E. Storer - Blood 2005 被引用: 2,927

  8. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

    著者: Daniel Sommermeyer, Michael Hudecek, Paula L. Kosasih, Tea Gogishvili, David G. Maloney, Cameron J. Turtle, Stanley R. Riddell - Leukemia 2015 被引用: 861

  9. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

    著者: Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed M. Hawkins, Colette Chaney, Sindhu Cherian, Xueyan Chen, Lorinda Soma, Brent L. Wood, Daniel Li, Shelly Heimfeld, Stanley R. Riddell, David G. Maloney - Science Translational Medicine 2016 被引用: 1,010

  10. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

    著者: Joshua A. Hill, Daniel Li, Kevin A. Hay, Margaret L. Green, Sindhu Cherian, Xueyan Chen, Stanley R. Riddell, David G. Maloney, Michael Boeckh, Cameron J. Turtle - Blood 2017 被引用: 566

  11. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade

    著者: Shivani Srivastava, Scott N. Furlan, Carla A. Jaeger-Ruckstuhl, Megha Sarvothama, Carolina Berger, Kimberly S. Smythe, Sarah M. Garrison, Jennifer M. Specht, Sylvia M. Lee, Robert A. Amezquita, Valentin Voillet, Vishaka Muhunthan, Sushma Yechan-Gunja, Smitha P.S. Pillai, Christoph Rader, A. McGarry Houghton, Robert H. Pierce, Raphaël Gottardo, David G. Maloney, Stanley R. Riddell - Cancer Cell 2020 被引用: 334

  12. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

    著者: Ana Cordeiro, Evandro D. Bezerra, Alexandre V. Hirayama, Joshua A. Hill, Qian Wu, Jenna Voutsinas, Mohamed L. Sorror, Cameron J. Turtle, David G. Maloney, Merav Bar - Biology of Blood and Marrow Transplantation 2019 被引用: 351

  13. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

    著者: Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena Perna, Sherilyn A. Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda - The Lancet 2023 被引用: 198

  14. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

    著者: Rebecca Gardner, David Wu, Sindhu Cherian, Min Fang, Laïla‐Aïcha Hanafi, Olivia Finney, Hannah Smithers, Michael C. Jensen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle - Blood 2016 被引用: 749

  15. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

    著者: Kevin A. Hay, Jordan Gauthier, Alexandre V. Hirayama, Jenna Voutsinas, Qian Wu, Daniel Li, Ted Gooley, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Gary Schoch, Aude G. Chapuis, Brian G. Till, Hans‐Peter Kiem, Jorge Ramos, Mazyar Shadman, Ryan D. Cassaday, Utkarsh Acharya, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle - Blood 2019 被引用: 401

  16. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

    著者: Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, K. OGASAWARA, Ana Kostić, Tanya Siddiqi - Blood 2023 被引用: 171

  17. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy

    著者: Alyssa Sheih, Valentin Voillet, Laïla‐Aïcha Hanafi, Hannah A. DeBerg, Masanao Yajima, Reed M. Hawkins, Vivian H. Gersuk, Stanley R. Riddell, David G. Maloney, Martin E. Wohlfahrt, Dnyanada Pande, Mark Enstrom, Hans‐Peter Kiem, Jennifer E. Adair, Raphaël Gottardo, Peter S. Linsley, Cameron J. Turtle - Nature Communications 2020 被引用: 268

  18. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

    著者: Gilles Salles, Martin Barrett, Robin Foà, J Maurer, Susan O’Brien, Nancy Valente, Michael Wenger, David G. Maloney - Advances in Therapy 2017 被引用: 608

  19. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

    著者: Caron A. Jacobson, Bradley D. Hunter, Robert Redd, Scott J. Rodig, Pei-Hsuan Chen, Kyle Wright, Mikel Lipschitz, Jerome Ritz, Yusuke Kamihara, Philippe Armand, Sarah Nikiforow, Michael Rogalski, Joseph Maakaron, Samantha Jaglowski, Marcela V. Maus, Yi‐Bin Chen, Jeremy S. Abramson, Justin Kline, Elizabeth Budde, Alex F. Herrera, Matthew Mei, Jonathon B. Cohen, Stephen D. Smith, David G. Maloney, Ajay K. Gopal, Matthew J. Frigault, Utkarsh Acharya - Journal of Clinical Oncology 2020 被引用: 345

  20. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

    著者: Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Jenna Voutsinas, Qian Wu, Ted Gooley, Daniel Li, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Utkarsh Acharya, Ryan D. Cassaday, Aude G. Chapuis, Tejaswini Dhawale, Paul C. Hendrie, Hans‐Peter Kiem, Ryan C. Lynch, Jorge Ramos, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle - Blood 2019 被引用: 336

  21. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

    著者: Nicolas Gazeau, Emily C. Liang, Qian Wu, Jenna Voutsinas, Pere Barba, Gloria Iacoboni, Mi Kwon, Juan Luis Reguera Ortega, Lucía López‐Corral, Rafael Hernani, Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Antonio Pérez‐Martínez, Richard T. Maziarz, Staci Williamson, Eneida R. Nemecek, Mazyar Shadman, Andrew J. Cowan, Damian J. Green, Erik L. Kimble, Alexandre V. Hirayama, David G. Maloney, Cameron J. Turtle, Jordan Gauthier - Transplantation and Cellular Therapy 2023 被引用: 135

  22. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

    著者: Jordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama, Salvatore Fiorenza, Alyssa Sheih, Cassie Chou, Erik L. Kimble, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Abby W Jamieson, Merav Bar, Ryan D. Cassaday, Aude G. Chapuis, Andrew J. Cowan, Damian J. Green, Hans‐Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle - Blood 2020 被引用: 212

  23. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

    著者: Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub‐Agha, Rashmi Khanal, Joseph D. Rosenblatt, Ronald L. Korn, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, A. Scott Jung, Harry Miao, Sara Beygi, Caron A. Jacobson - Blood 2023 被引用: 141

  24. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

    著者: Andrew J. Cowan, Margot J. Pont, Blythe Sather, Cameron J. Turtle, Brian G. Till, Edward N. Libby, David G. Coffey, Sherilyn A. Tuazon, Brent L. Wood, Ted Gooley, Vicky Q Wu, Jenna Voutsinas, Xiaoling Song, Mazyar Shadman, Jordan Gauthier, Aude G. Chapuis, Filippo Milano, David G. Maloney, Stanley R. Riddell, Damian J. Green - The Lancet Oncology 2023 被引用: 98